Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jonathan B. Pollett"'
Autor:
Mitra Lavasani, Jonathan B Pollett, Arvydas Usas, Seth D Thompson, Aaron F Pollett, Johnny Huard
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82173 (2013)
Here, we demonstrated the differentiation potential of murine muscle-derived stem/progenitor cells (MDSPCs) toward myogenic, neuronal, and glial lineages. MDSPCs, following transplantation into a critical-sized sciatic nerve defect in mice, showed fu
Externí odkaz:
https://doaj.org/article/51c5730b298d4bc3a8d58ca5725ec711
Autor:
Donna B. Stolz, Bin Sun, Seth D. Thompson, Johnny Huard, Aiping Lu, Jonathan B. Pollett, Katherine A. Clark, Mitra Lavasani, Arvydas Usas, Bruno Péault
Publikováno v:
Journal of Clinical Investigation. 124:1745-1756
Peripheral nerve injuries and neuropathies lead to profound functional deficits. Here, we have demonstrated that muscle-derived stem/progenitor cells (MDSPCs) isolated from adult human skeletal muscle (hMDSPCs) can adopt neuronal and glial phenotypes
Autor:
Jonathan B. Pollett, Srinivas Murali, Kelly J. Shields, Michael J. Passineau, Raymond L. Benza
Publikováno v:
The Journal of Heart and Lung Transplantation. 32:746-749
Endothelial dysfunction is a hallmark of pulmonaryarterial hypertension (PAH). Although the exact roleendothelial dysfunction plays in the initiation or progressionof PAH is not yet clear, impaired apoptosis and aberrantsignaling in endothelial cells
Autor:
Burhan Gharaibeh, Johnny Huard, Guangheng Li, Jonathan B. Pollett, Bruno Péault, Lauren Drowley, Arvydas Usas, Bin Sun, William C.W. Chen, Bridget M. Deasy, Bo Zheng
Publikováno v:
Journal of Orthopaedic Research. 31:1089-1095
We have previously reported the high regenerative potential of murine muscle-derived stem cells (mMDSCs) that are capable of differentiating into multiple mesodermal cell lineages, including myogenic, endothelial, chondrocytic, and osteoblastic cells
Autor:
Michael A. Rudnicki, Jonathan B. Pollett, James H. Cummins, Bin Sun, Johnny Huard, Aiping Lu, Baohong Cao
Publikováno v:
Gene Therapy. 15:1116-1125
In an attempt to determine whether muscle-derived stem cells are distinct from satellite cells, we investigated whether muscle-derived stem cells could be isolated from the skeletal muscle of Pax7-deficient mice, which have been shown to be devoid of
Autor:
Jonathan B. Pollett, Karin A. Corsi, Guangheng Li, Julie A. Phillippi, Arvydas Usas, Johnny Huard
Publikováno v:
Journal of Bone and Mineral Research. 22:1592-1602
This study compared the osteogenic differentiation of F-MDSCs and M-MDSCs. Interestingly, M-MDSCs expressed osteogenic markers and underwent mineralization more readily than F-MDSCs; a characteristic likely caused by more osteoprogenitor cells within
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 35
Background: Endothelial cells (EC) dysfunction is linked to the development of CAD. Current studies rely on ECs harvested from the umbilical vein or bovine aorta because of the ease of isolation. This fails to account for phenotypic variations and ma
Autor:
Zhihua Li, Suzanne Trudel, A. Keith Stewart, Joshua Paterson, Xiao-Yan Wen, Jonathan B. Pollett, Esther Masih-Khan, Hong Chang
Publikováno v:
British Journal of Haematology. 124:595-603
Summary Dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the translocation t(4;14)(p16;q32) occurs in 15% of multiple myeloma (MM) patients and confers a growth and survival advantage to malignant plasma cells. As FGFR3 is a molecular
Autor:
Jonathan B. Pollett, Mitra Lavasani, Seth D. Thompson, Aaron Pollett, Arvydas Usas, Johnny Huard
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82173 (2013)
PLoS ONE
PLoS ONE
Here, we demonstrated the differentiation potential of murine muscle-derived stem/progenitor cells (MDSPCs) toward myogenic, neuronal, and glial lineages. MDSPCs, following transplantation into a critical-sized sciatic nerve defect in mice, showed fu
Publikováno v:
Blood. 100:3819-3821
Translocations involving the immunoglobulin heavy-chain switch region and fibroblast growth factor receptor 3 (FGFR3) are identified in 10% to 15% of patients with myeloma. In previous research we overexpressed FGFR3 or the constitutively active FGFR